Abstract:Cardiac hypertrophy is the most prevalent compensatory heart disease that ultimately leads to spontaneous heart failure. Mounting evidence suggests that microRNAs (miRs) and endogenous hydrogen sulfide (H2S) play a crucial role in the regulation of cardiac hypertrophy. In this study, we aimed to investigate whether inhibition of miR-27a could protect against cardiac hypertrophy by modulating H2S signaling. We established a model of cardiac hypertrophy by obtaining hypertrophic tissue from mice subjected to transverse aortic constriction (TAC) and from cells treated with angiotensin-II. Molecular alterations in the myocardium were quantified using quantitative real time PCR (qRT-PCR), Western blotting, and ELISA. Morphological changes were characterized by hematoxylin and eosin (HE) staining and Masson's trichrome staining. Functional myocardial changes were assessed using echocardiography. Our results demonstrated that miR-27a levels were elevated, while H2S levels were reduced in TAC mice and myocardial hypertrophy. Further luciferase and target scan assays confirmed that cystathionine-γ-lyase (CSE) was a direct target of miR-27a and was negatively regulated by it. Notably, enhancement of H2S expression in the heart was observed in mice injected with recombinant adeno-associated virus vector 9 (rAAV9)-anti-miR-27a and in cells transfected with a miR-27a inhibitor during cardiac hypertrophy. However, this effect was abolished by co-transfection with CSE siRNA and the miR-27a inhibitor. Conversely, injecting rAAV9-miR-27a yielded opposite results. Interestingly, our findings demonstrated that glucagon-like peptide-1 (GLP-1) agonists could mitigate myocardial damage by down-regulating miR-27a and up-regulating CSE. In summary, our study suggests that inhibition of miR-27a holds therapeutic promise for the treatment of cardiac hypertrophy by increasing H2S levels. Furthermore, our findings unveil a novel mechanism of GLP-1 agonists involving the miR-27a/H2S pathway in the management of cardiac hypertrophy.

miR-93 and synaptotagmin-7: two novel players in the regulation of autophagy during cardiac hypertrophy

Cardiac Hypertrophy and Dysfunction Induced by Overexpression of Mir-214 in Vivo

Synaptotagmin-7 mediates cardiac hypertrophy by targeting autophagy

Sympathoexcitation in Rats with Chronic Heart Failure Depends on Homeobox D10 and MicroRNA-7b Inhibiting GABBR1 Translation in Paraventricular Nucleus

MicroRNA-214 contributes to Ang II-induced cardiac hypertrophy by targeting SIRT3 to provoke mitochondrial malfunction

Mir-96 Inhibits Cardiac Hypertrophy by Targeting Growth Factor Receptor-Bound 2.

The crucial relationship between miRNA-27 and CSE/H2S, and the mechanism of action of GLP-1 in myocardial hypertrophy

Roles of SIRT3 in Heart Failure: from Bench to Bedside.

MiR-27a-3p/Hoxa10 Axis Regulates Angiotensin II-Induced Cardiomyocyte Hypertrophy by Targeting Kv4.3 Expression

Cardiac Hypertrophy Is Positively Regulated by MicroRNA miR-23a

Overexpression of Microrna-99a Attenuates Cardiac Hypertrophy

MicroRNAs: novel regulators in cardiac development and disease

ASSA13-03-3 the Research for Molecular Mechanism of Mir-93 Negative Regulation on Stat3 Transduction Pathway in Cardiac Hypertrophy

Mir-199a Impairs Autophagy and Induces Cardiac Hypertrophy Through Mtor Activation

miR-208a in Cardiac Hypertrophy and Remodeling

Microrna-340-5p Functions Downstream Of Cardiotrophin-1 To Regulate Cardiac Eccentric Hypertrophy And Heart Failure Via Target Gene Dystrophin

Regulation of miR-199a expression by AMPK in cardiac tissues

MiR-378 Inhibits Angiotensin II-Induced Cardiomyocyte Hypertrophy by Targeting AKT2

Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy.

Identification and validation of autophagy‑related genes in hypertrophic cardiomyopathy

Mir-9 and NFATc3 Regulate Myocardin in Cardiac Hypertrophy